Latest News for: pahs
Edit
Natco Pharma launches generic drug for PAH in the U.S.
The Hindu 20 Aug 2025
Bosentan TFOS, 32mg, had estimated sales of $10 million in the U.S. for 12 months ending June’25, the Hyderabad-based company said ....
Edit
Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH (Form 8-K) (Gossamer Bio Inc)
Public Technologies 16 Jun 2025
) Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH. - Enrollment Completed in Ongoing Registrational PROSERA Phase 3 Study in PAH -.
Edit
Cereno Scientific shares 4-month follow-up data from Expanded Access Program in line with Phase IIa trial results of CS1 in rare disease PAH (Cereno Scientific AB)
Public Technologies 16 Jun 2025
Drug candidate CS1, an epigenetic modulating HDAC-inhibitor, has a strong potential to transform the lives of PAH patients as a well-tolerated oral therapy with a favorable safety and tolerability profile and disease-modifying effects.
Edit
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
Nasdaq Globe Newswire 02 Jun 2025
Food and Drug Administration (FDA) approval of YUTREPIA on May 23, 2025, for the treatment of pulmonary arterial hypertension (PAH) and ...
Edit
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD (Form 8-K) (Liquidia Corporation)
Public Technologies 02 Jun 2025
Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).
Edit
Results from the Cibotercept TROPOS PAH Phase 2 Trial (8f19c4) (Keros Therapeutics Inc)
Public Technologies 29 May 2025
Edit
U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary ...
Nasdaq Globe Newswire 23 May 2025
Edit
U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) (Form 8-K) (Liquidia Corporation)
Public Technologies 23 May 2025
Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).
- 1